A detailed history of Fulcrum Equity Management transactions in Eli Lilly & CO stock. As of the latest transaction made, Fulcrum Equity Management holds 562 shares of LLY stock, worth $447,166. This represents 0.43% of its overall portfolio holdings.

Number of Shares
562
Previous 405 38.77%
Holding current value
$447,166
Previous $366,000 35.79%
% of portfolio
0.43%
Previous 0.34%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 21, 2024

BUY
$772.14 - $960.02 $121,225 - $150,723
157 Added 38.77%
562 $497,000
Q2 2024

Jul 19, 2024

BUY
$724.87 - $909.04 $293,572 - $368,161
405 New
405 $366,000
Q4 2022

Jul 07, 2023

BUY
$321.55 - $374.67 $180,389 - $210,189
561 New
561 $205,000
Q4 2022

Jan 10, 2023

BUY
$321.55 - $374.67 $180,389 - $210,189
561 New
561 $0
Q2 2022

Jul 18, 2022

BUY
$278.73 - $327.27 $216,294 - $253,961
776 New
776 $252,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Fulcrum Equity Management Portfolio

Follow Fulcrum Equity Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fulcrum Equity Management, based on Form 13F filings with the SEC.

News

Stay updated on Fulcrum Equity Management with notifications on news.